Incretin-based Drugs Market Companies Few of the prominent players operating in the incretin-based drugs industry include: AstraZeneca Boehringer Ingelheim Eli Lilly and Company Merck Novo Nordisk Pfizer Sanofi Takeda Pharmaceutical Company Teva Pharmaceuticals AstraZeneca AstraZeneca holds key position in the market through its GLP-1 receptor agonist (Byetta and Bydureon) and DPP-4 inhibitors (Onglyza)
Peptides : Peptides are amino acids that signal skin to produce more collagen and elastin, helping improve firmness
Additionally, GLP-1 modulates the phosphorylation of AKT, ERK, GSK-3B, and mTOR to increase cell viability and growth (25, 26)
The most commonly observed include: Gastrointestinal issues such as nausea, vomiting, or diarrhea Injection site reactions (pain, redness, or itching) Hypoglycemia (low blood sugar) , especially when combined with insulin or sulfonylureas Increased heart rate in some individuals Rare allergic reactions Summary GIP/GLP-1 is a synthetic peptide analog studied in preclinical models for its interaction with GIP and GLP-1 receptors, which are central to metabolic and hormonal signaling pathways
It supports fat metabolism, energy levels, and appetite regulation when used consistently alongside healthy habits
Together, you can develop a tapering plan rather than abruptly discontinuing medication